Review Article

J. innov.appl. pharm. Sci, 9[3] 2024, 1-6

Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: www.saapjournals.org ISSN: 2455-5177

NANOTECHNOLOGY IN PHARMACEUTICAL MANUFACTURING: PRESENT INNOVATIONS AND FUTURE OPPORTUNITIES

Sanket J Soni*[1], Ankitkumar N Patel [2]

*[1] Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA.

[2] Director of Formulation, Department of Formulation R&D, Amneal Pharmaceuticals, New Jersey, USA.

Article History

Received: 03-09-2024
Revised: 16-09-2024
Accepted: 11-10-2024

Keywords:
Nanotechnology, Drug Manufacturing, Nanocarriers, Nano formulations, Nanofabrication, Personalized Medicine, Nanobots, Gene Therapy, CRISPR, Pharmaceutical Industry

Abstract

Nanotechnology has revolutionized the pharmaceutical industry by enabling the design and delivery of drugs with enhanced precision, efficacy, and safety. This review provides a comprehensive overview of current trends and future prospects in nanotechnology-based drug manufacturing. It explores the application of nanocarriers, such as liposomes, micelles, and nanoparticles, which have improved drug bioavailability, targeted delivery, and reduced side effects. Nano formulations like solid lipid nanoparticles (SLNs) and polymeric nanoparticles are also highlighted for their role in controlled drug release and cancer treatment. Technological innovations, including advanced nanofabrication techniques and 3D printing, are driving the development of complex drug formulations. The review also addresses the challenges in scaling production and the evolving regulatory landscape. Future prospects include the use of nanobots and advanced Nano machines for drug delivery, the integration of nanotechnology in gene therapy and CRISPR, and the exploration of new research and investment opportunities. Ethical and safety considerations, such as the long-term effects of nanomaterials on human health and the environment, are discussed. This review underscores the transformative potential of nanotechnology in drug manufacturing, offering insights into its role in shaping the future of the pharmaceutical industry.

***Corresponding Author**
Sanket J Soni

https://doi.org/10.37022/jiaps.v9i3.634

Production and Hosted by
www.saapjournals.org

Introduction

Nanotechnology involves the manipulation and control of matter at the nanoscale, typically between 1 to 100 nanometers. At this scale, materials exhibit unique physical, chemical, and biological properties that differ significantly from their bulk counterparts [1]. In drug manufacturing, nanotechnology has emerged as a revolutionary tool that enables the design and delivery of drugs with enhanced precision, efficacy, and safety. By leveraging nanotechnology, pharmaceutical scientists can create novel drug formulations that improve solubility, stability, and targeted delivery, ultimately leading to better therapeutic outcomes [2].

The application of nanotechnology in pharmaceuticals has evolved over the past few decades. Initially, the focus was on the development of Nanocarriers such as liposomes and nanoparticles for drug delivery. These early innovations laid the groundwork for more sophisticated nano-based drug delivery systems, including micelles, dendrimers, and polymeric nanoparticles [3]. The late 20th and early 21st centuries saw significant advancements in Nano formulations, leading to the commercialization of several nanotechnology-based drugs. Today, nanotechnology continues to push the boundaries of drug manufacturing, with ongoing research exploring new materials, techniques, and applications that promise to revolutionize the industry further [4].

2. Scope and Objectives

This review aims to provide a comprehensive overview of the current trends and future prospects of nanotechnology in drug manufacturing. The article will explore the various types of Nano carriers and Nano formulations currently in use and the technological innovations driving the field forward. Additionally, it will examine the challenges associated with scaling up nanotechnology-based drug production, including regulatory and quality control issues. Finally, the review will offer insights into emerging trends and potential future developments, focusing on the implications of nanotechnology for personalized medicine, gene therapy, and other cutting-edge areas. By highlighting these key aspects, the review seeks to underscore the transformative potential of nanotechnology in the pharmaceutical industry and its role in shaping the future of drug manufacturing.

3. Current Trends in Nanotechnology for Drug Manufacturing

Nanocarriers and Drug Delivery Systems

Liposomes, Micelles, and Nanoparticles Nanocarriers, such as liposomes, micelles, and nanoparticles, have become crucial tools in drug delivery due to their ability to enhance the therapeutic index of drugs. Liposomes, spherical vesicles composed of phospholipid bilayers, have been widely used to encapsulate hydrophilic and hydrophobic drugs, protecting them from degradation and ensuring their delivery to specific target sites. Micelles, formed from amphiphilic molecules, are particularly effective for delivering poorly soluble drugs. Nanoparticles, which can be composed of a variety of materials such as polymers, lipids, or metals, offer versatile platforms for controlled drug release and targeted delivery. These Nanocarriers are engineered to optimize drug delivery by improving bioavailability, reducing systemic side effects, and enabling the precise targeting of diseased tissues, such as tumours, thereby maximizing therapeutic efficacy [5,6].

Advantages over Traditional Methods The utilization of nanotechnology in drug delivery offers several significant advantages over traditional drug delivery methods. Firstly, nanocarriers can improve the bioavailability of drugs by enhancing their solubility and stability in biological environments. This is particularly beneficial for drugs with poor water solubility, which can now be delivered effectively to their target sites. Secondly, nanocarriers can reduce side effects by enabling targeted drug delivery, where the drug is released specifically at the site of action, minimizing exposure to healthy tissues. Finally, nanotechnology allows for controlled and sustained drug release, which can maintain therapeutic drug levels over an extended period, reducing the need for frequent dosing and improving patient compliance. These advantages collectively contribute to the enhanced therapeutic efficacy of nano-based drug formulations [7,8].

Nano formulations

Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) represent advanced lipid-based Nano formulations that are gaining traction in drug delivery. SLNs are composed of solid lipids at room and body temperature, offering a matrix for the controlled release of encapsulated drugs [9]. These nanoparticles provide advantages such as improved drug stability, controlled release, and the ability to carry both hydrophilic and lipophilic drugs. NLCs, on the other hand, are second-generation lipid nanoparticles that incorporate liquid lipids into the solid lipid matrix, resulting in a more flexible structure that can accommodate higher drug loading and reduce drug expulsion during storage. Both SLNs and NLCs are being explored for their potential in sustained and controlled drug release, particularly for chronic diseases requiring long-term therapy [10].

Polymeric Nanoparticles Polymeric nanoparticles, composed of biodegradable and biocompatible polymers such as poly (lactic-co-glycolic acid) (PLGA), are extensively used for encapsulating and delivering hydrophobic drugs. These nanoparticles protect the drug from degradation, enhance solubility, and allow for controlled and targeted drug release. Polymeric nanoparticles can be engineered to respond to specific stimuli, such as pH or temperature, enabling site-specific drug release in response to the local environment. This makes them particularly useful for the treatment of diseases such as cancer, where targeted delivery and controlled release are critical for therapeutic success [11].

Nano-based Drug Design and Development

Nano-emulsions and Nanosuspensions Nano emulsions and nanosuspensions are two essentialNano formulations that are crucial in improving the solubility and stability of poorly soluble drugs. Nano emulsions are thermodynamically stable dispersions of oil and water stabilized by surfactants, with droplet sizes in the nanometer range. These formulations enhance the solubility of lipophilic drugs, improve absorption, and provide a vehicle for delivering drugs through various routes, including oral, topical, and parenteral. On the other hand, nanosuspensions consist of pure drug particles stabilized by surfactants or polymers, which are suspended in a liquid medium. These nanoscale suspensions improve the dissolution rate of poorly soluble drugs, enhancing their bioavailability and therapeutic effectiveness [12].

Nanoscale Drug Screening and Discovery Nanotechnology is also revolutionising drug discovery by enabling nanoscale drug screening and high-throughput discovery processes. Nanoscale screening platforms allow for the rapid identification of potential drug candidates by testing thousands of compounds simultaneously at the nanoscale level. This accelerates the drug discovery process and increases the accuracy and efficiency of identifying promising drug candidates. Additionally, nanotechnology-based tools, such as Nano cantilevers and Nano pore sensors, are being used to study drug-target interactions at the molecular level, providing deeper insights into drug mechanisms and aiding in the design of more effective therapeutics [13].

Nanotechnology in Personalized Medicine

Nano diagnostics and Theranostics Nanotechnology plays a pivotal role in personalized medicine through the development of Nano diagnostics and theranostics. Nano diagnostics involve the use of nanoscale materials and devices for early detection and diagnosis of diseases. These tools can detect biomarkers at very low concentrations, enabling earlier diagnosis and more accurate monitoring of disease progression. Theranostics combines diagnostic and therapeutic functions in a single Nano device, allowing for simultaneous detection and treatment of diseases. For example, a theranostic nanoparticle can deliver a therapeutic agent to a tumour while simultaneously providing imaging contrast to monitor the treatment's effectiveness in real-time [14].

Tailored Drug Delivery Nanotechnology enables the development of tailored drug delivery systems that cater to the specific needs of individual patients. By understanding a patient's disease's genetic and molecular profile,
nanotechnology can be used to design personalized drug formulations that target the disease at its source with high precision. This approach minimizes the risk of adverse effects and maximizes therapeutic outcomes. Additionally, nanocarriers can be functionalized with ligands that bind to receptors expressed on diseased cells. This ensures that the drug is delivered exactly where needed, enhancing the efficacy and safety of personalised treatment regimens [15].

Table 1: Current Trends in Nanotechnology for Drug Manufacturing

Category	Subcategory	Description
Nanocarriers and Drug Delivery Systems	Liposomes, Micelles, and Nanoparticles	- Targeted drug delivery - Protection from degradation - Enhanced bioavailability
	Advantages over Traditional Methods	- Improved solubility and stability - Reduced systemic side effects - Controlled release
Nanoformulations	Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)	- Sustained and controlled drug release - Compatibility with both hydrophilic and lipophilic drugs
	Polymeric Nanoparticles	- Enhanced drug protection - Stimuli-responsive release - Application in cancer treatment
Nano-based Drug Design and Development	Nanoemulsions and Nanosuspensions	- Improved solubility and stability - Enhanced bioavailability - Versatile administration routes
	Nanoscale Drug Screening and Discovery	- Faster drug discovery - Increased accuracy in identifying drug candidates
Nanotechnology in Personalized Medicine	Nano diagnostics and Theranostics	- Early diagnosis - Real-time monitoring - Combined therapeutic and diagnostic functions
	Tailored Drug Delivery	- Reduced adverse effects - High-precision targeting - Enhanced therapeutic outcomes

3. Technological Innovations in Nano manufacturing

Advanced Nanofabrication Techniques

Top-Down vs. Bottom-Up ApproachesNano manufacturing can be broadly categorized into two main approaches: top-down and bottom-up. The top-down approach involves the reduction of bulk materials into nanoscale structures through methods such as lithography, milling, and etching. This approach is commonly used for creating nanostructures with precise dimensions, but issues like surface defects and material waste can limit it. Conversely, the bottom-up approach builds nanoscale materials atom by atom or molecule by molecule, often using chemical synthesis or self-assembly techniques. This method allows for greater control over the material's composition and properties, making it ideal for creating complex nanostructures with specific functionalities. Both approaches play vital roles in the production of nanoscale drug formulations, with the choice of technique depending on the desired application and material properties[16,17].

3D Printing and Nanotechnology 3D printing, or additive manufacturing, is emerging as a powerful tool in nanotechnology, particularly for the production of complex nano-drug formulations. By layering materials with nanoscale precision, 3D printing allows for the fabrication of intricate drug delivery systems that were previously unattainable with traditional manufacturing methods. This technology enables the creation of personalized medicine by allowing the customization of drug formulations to meet individual patient needs. Additionally, 3D printing can incorporate multiple drugs into a single formulation, allowing multi-functional drug delivery systems to be developed. The integration of nanotechnology with 3D printing opens new possibilities for producing tailored and complex drug formulations with unprecedented precision and functionality [18, 19].

Regulatory and Quality Control Aspects

Challenges in Scale-Up and Manufacturing Scaling up the production of nanotechnology-based drugs from the laboratory to commercial manufacturing presents significant challenges. The complexity of nanomaterials and the need for precise control over their properties makelarge-scale production difficult. Consistency in product quality is critical, yet achieving uniformity in size, shape, and functionality of nanoparticles on a large scale can be challenging. Moreover, the high cost of Nano manufacturing processes and the need for specialized equipment and facilities further complicate the scale-up process. Addressing these challenges requires ongoing innovation in manufacturing techniques and collaboration between industry and regulatory bodies to establish standardized methods [20].

Regulatory Considerations The regulatory landscape for nanotechnology in drug manufacturing is still evolving. Nanotechnology introduces unique challenges in terms of safety, efficacy, and quality, requiring regulatory agencies to develop specific guidelines for nano-based drugs. The complexity of nanomaterials demands a thorough evaluation of their pharmacokinetics, bio distribution, toxicity, and environmental impact. Regulatory bodies like the FDA and EMA are working to establish frameworks that address these challenges, but the rapidly evolving nature of nanotechnology often outpaces regulatory developments. Ensuring compliance with these regulations is crucial for the successful commercialization of nano-based drugs, requiring manufacturers to engage in rigorous testing and validation processes [21].

Automation and Process Analytical Technology (PAT)

Real-time Monitoring and Control Process Analytical Technology (PAT) is revolutionising Nano manufacturing by enabling real-time monitoring and control of the production process. PAT tools allow for continuous assessment of critical quality attributes, such as particle size, shape, and distribution, during manufacturing. These real-time data enables manufacturers to make immediate adjustments, ensuring consistent product quality and reducing the likelihood of batch failures. Automation further enhances the precision of nano-drug production by minimising human error and increasing the efficiency of the manufacturing process. Integrating PAT and automation in Nano manufacturing improves the quality of nano-based drugs and accelerates the scale-up process, making bringing new Nano medicines to market easier.These technological innovations in Nano manufacturing are driving the field forward, enabling the production of more sophisticated and effective nano-based drugs. However, they also present new challenges that must be addressed through continued research, collaboration, and regulatory adaptation. [22]

Table 2: Summarising the Technological Innovations in Nano manufacturing

Category	Subcategory	Key Points
Advanced Nanofabrication Techniques	Top-Down vs. Bottom-Up Approaches	- Top-down: precise dimensions, potential material waste - Bottom-up: greater control over composition and properties
	3D Printing and Nanotechnology	- Enables customization of drug formulations - Allows for incorporation of multiple drugs into a single formulation
Regulatory and Quality Control Aspects	Challenges in Scale-Up and Manufacturing	- Difficulty in achieving consistency on a large scale - High cost and specialized equipment requirements
	Regulatory Considerations	- Regulatory agencies developing frameworks - Importance of thorough evaluation of nanomaterials
Automation and Process Analytical Technology (PAT)	Real-time Monitoring and Control	- Continuous assessment of critical quality attributes - Automation reduces human error and improves manufacturing efficiency

Product Name	Application	Manufacturer/Developer
Doxil (Doxorubicin HCl Liposome Injection)	Cancer treatment (e.g., ovarian cancer, multiple myeloma)	Janssen Pharmaceuticals
Abraxane (Paclitaxel Albumin-bound Particles)	Cancer treatment (e.g., breast cancer, pancreatic cancer)	Celgene (now part of Bristol-Myers Squibb)
Onivyde (Irinotecan Liposome Injection)	Pancreatic cancer treatment	Ipsen Biopharmaceuticals
Feraheme (Ferumoxytol)	Iron replacement therapy for anaemia	AMAG Pharmaceuticals
Vivitrol (Naltrexone Microparticles)	Opioid and alcohol dependence treatment	Alkermes
Rapamune (Sirolimus Nanocrystal)	Immunosuppressant for organ transplant patients	Pfizer
Vyxeos (Cytarabine and Daunorubicin Liposome Injection)	Acute myeloid leukemia (AML) treatment	Jazz Pharmaceuticals
Arestin (Minocycline Hydrochloride Microspheres)	Periodontal disease treatment	OraPharma

4. Future Prospects and Challenges

Nanobots and Advanced Nano machines Nanobots and advanced Nano machines represent some of the most futuristic concepts in nanotechnology for drug delivery and disease treatment. These nanoscale devices are designed to perform specific tasks at the molecular level, such as targeting and destroying cancer cells, repairing damaged tissues, or delivering drugs directly to specific cells. The potential of nanobots lies in their ability to navigate through the body with high precision, offering treatments that are both minimally invasive and highly effective. Although still in the experimental stages, advancements in nanotechnology are bringing these concepts closer to reality, with ongoing research focused on improving their functionality, safety, and scalability [23 ,24].

Nanotechnology in Gene Therapy and CRISPR Nanotechnology is poised to play a crucial role in advancing gene therapy and

CRISPR technologies. Nanoparticles can be used as carriers for delivering genetic material or CRISPR components directly into cells, offering a more efficient and targeted approach to gene editing. This is particularly important for treating genetic disorders, where precise delivery of therapeutic genes or gene-editing tools is critical. Nanotechnology enhances delivery efficiency, reduces off-target effects, and improves the safety of gene therapy and CRISPR applications. As research in this area progresses, nanoscale technologies are expected to unlock new possibilities in treating a wide range of genetic diseases [25, 26].

Ethical and Safety Considerations

Long-Term Safety and Toxicity Nanomaterials' long-term safety and toxicity in the human body remain significant concerns. While nanotechnology offers many benefits, the unique properties of nanomaterials also pose potential risks. Nanoparticles can interact with biological systems in unpredictable ways, leading to concerns about their accumulation in tissues, potential toxicity, and long-term health effects. Comprehensive studies are needed to assess the biocompatibility, bio distribution, and elimination of nanomaterials. Addressing these safety concerns is essential for the responsible development and widespread adoption of nanotechnology in drug manufacturing [27].

Environmental Impact The environmental impact of nanotechnology in pharmaceuticals is another important consideration. The production, use, and disposal of nanomaterials could have ecological consequences, such as the release of nanoparticles into the environment, where they may accumulate and affect ecosystems. Understanding the environmental behavior of nanomaterials, including their potential for bioaccumulation and toxicity to wildlife, is critical for developing sustainable nanotechnology practices. Research in this area is needed to identify potential risks and implement strategies to mitigate the environmental impact of nanotechnology in drug manufacturing [26].

Commercialisation and Market Trends

Growth Projections The market for nanotechnology in drug manufacturing is expected to experience significant growth in the coming years. As more nano-based drugs receive regulatory approval and enter the market, the demand for nanotechnology in pharmaceuticals is projected to rise. The global Nano medicine market is estimated to reach billions of dollars, driven by the increasing adoption of nanotechnology in drug development, diagnostics, and personalized medicine. This growth is supported by advancements in Nano manufacturing techniques, regulatory frameworks, and the rising prevalence of chronic diseases that require innovative treatment solutions [28,29].

Investment and Research Opportunities With the growing market potential, there are ample opportunities for investment and research in nanotechnology for drug manufacturing. Key areas for future research include the development of safer and more efficient nanocarriers, exploration of new nanomaterials, and advancement of Nano manufacturing technologies. Additionally, there is a need for research focused on understanding nanotechnology's long-term safety, environmental impact, and ethical implications. Investment in these areas will be crucial for driving innovation, ensuring the safe and effective use of nanotechnology, and maintaining a competitive edge in the pharmaceutical industry [30-32].

Conclusion

Nanotechnology has emerged as a pivotal tool in drug manufacturing, offering novel solutions to some of the industry's most pressing challenges. Current trends in nanotechnology-based drug manufacturing include using various nanocarriers for targeted drug delivery, developing advanced Nano formulations for sustained and controlled release, and applying innovative nanofabrication techniques such as 3D printing. These advancements have significantly improved the therapeutic efficacy of drugs, reduced side effects, and enabled personalized medicine. However, the field faces challenges in scaling up production and navigating the complex regulatory landscape. Future prospects are promising, with emerging technologies like nanobots and CRISPR poised to further revolutionize drug delivery and gene therapy. Additionally, ongoing research and investment are crucial for addressing the long-term safety, toxicity, and environmental impact of nanomaterials. These innovations will likely shape the future of drug manufacturing, making nanotechnology a cornerstone of modern pharmaceutical development. Continued collaboration between researchers, industry leaders, and regulatory bodies will be essential to harness the full potential of nanotechnology, ensuring its safe and effective integration into mainstream drug manufacturing.

Funding

No

Acknowledgement

Nil

Conflict of Interest

No conflict of interest.

Informed Consent

Not applicable.

Ethical Statement

Not applicable.

Author Contribution

Sanket J Soni, Ankitkumar N Patel both are contributed equally.

References

1. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-47.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71.
3. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-92.
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
5. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

6. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60.
7. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-98.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1-3):149-68.
9. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
10. Namballa M, Adimulapu A, Jesudasan RE. QbD Assisted Optimization of Microwave-assisted Synthesis of Polyacrylamide Grafted Tragacanth: Characterization and Instrumental Analysis. Current Microwave Chemistry. 2024 Apr 1;11(1):16-29.
11. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
12. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
13. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. AngewChem Int Ed Engl. 2009;48(5):872-97.
14. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-51.
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
16. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-63.
17. Sailor MJ, Park JH. Hybrid nanoparticles for detection and treatment of cancer. Adv Mater. 2012;24(28):3779-802.
18. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6(3):307-18.
19. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech 19, 1358–1366 (2018).
20. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia 80, 1211–1224 (2017).
21. Kakulamarri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. J Pharm Drug Deliv Res 5:3
22. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
23. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
24. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-66.
25. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Guo R, Chen H. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-32.
26. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3(1):20-31.
27. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005-23.
28. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biological effects. Nanoscale. 2011;3(3):1167-85.
29. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-9.
30. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-91.
31. Prasad RY, McGee JK, Killius MG, Suarez DA, Blackman CF, DeMarini DM, Simmons SO. Investigating nanoparticles in drug delivery, pulmonary toxicity, and cancer therapy. Toxicol Sci. 2013;132(2):340-51.
32. Wang F, Yu M, Yan X, Liu X, Zhao Y. Dendrimer-based nanoparticles for cancer diagnosis and therapy. J Control Release. 2017;259:136-48.